REGENXBIO Inc. (RGNX): Revenue
$170.44M
Year ended 2025-12-31
$174.48M
Trailing 12 months to 2026-06-30
+14.8%
3-year compound annual growth
+2.0%
5-year compound annual growth
+36.5%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $170.44M | +104.5% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $83.33M | -7.7% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $90.24M | -19.9% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $112.72M | -76.0% | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $470.35M | +204.3% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $154.57M | +338.7% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $35.23M | -83.9% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $218.50M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $10.39M | +126.5% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $4.59M | -39.5% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $7.59M | +24.0% | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | $6.12M | +0.5% | 2017-03-07, From 2014-01-01 |
| 2013-12-31 | $6.09M | n/a | 2016-03-03, From 2013-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $170.44M | +104.5% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $170.16M | -25.1% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $178.03M | +195.3% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $139.74M | +120.0% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $123.67M | +63.5% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $237.26M | +726.7% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $120.77M | -6.3% |
| Agenus Inc (AGEN) | 2025-12-31 | $114.20M | +10.4% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $113.29M | +668.3% |
Compare RGNX, DNA, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗